Get the Stockscreener App
1.80
0.55%
-0.01
Tscan Therapeutics Inc stock is traded at $1.80, with a volume of 189.47K.
It is down -0.55% in the last 24 hours and up +1.69% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$1.81
Open:
$1.8
24h Volume:
189.47K
Relative Volume:
0.35
Market Cap:
$94.17M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-1.0056
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
+9.76%
1M Performance:
+1.69%
6M Performance:
-12.20%
1Y Performance:
-68.91%
1-Day Range:
$1.79
$1.8594
1-Week Range:
$1.60
$1.8594
52-Week Range:
$1.02
$6.225
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.80 | 102.71M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Visualizing TScan Therapeutics Inc. stock with heatmapsPortfolio Profit Report & Daily Oversold Bounce Ideas - Newser
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates - MSN
Real time scanner hits for TScan Therapeutics Inc. explainedCPI Data & Expert Approved Momentum Ideas - Newser
Statistical indicators supporting TScan Therapeutics Inc.’s strengthGDP Growth & AI Forecast Swing Trade Picks - Newser
Measuring TScan Therapeutics Inc.’s beta against major indices2025 Market Overview & Precise Swing Trade Entry Alerts - Newser
What machine learning models say about TScan Therapeutics Inc.Layoff News & Smart Swing Trading Techniques - Newser
What Fibonacci levels say about TScan Therapeutics Inc. reboundJuly 2025 News Drivers & Weekly High Return Stock Forecasts - Newser
Detecting price anomalies in TScan Therapeutics Inc. with AI2025 Top Decliners & Consistent Return Investment Signals - Newser
Combining machine learning predictions for TScan Therapeutics Inc.Trade Risk Report & AI Enhanced Trade Execution Alerts - Newser
Equities Analysts Offer Predictions for TCRX Q3 Earnings - Defense World
Should you hold or exit TScan Therapeutics Inc. now2025 Breakouts & Breakdowns & Free Long-Term Investment Growth Plans - Newser
TScan Therapeutics Inc. stock trend forecastMarket Trend Report & Growth Focused Entry Reports - Newser
What makes TScan Therapeutics Inc. stock price move sharplyGold Moves & Free Technical Pattern Based Buy Signals - thegnnews.com
Is TScan Therapeutics Inc. a momentum stockDip Buying & Low Risk Entry Point Guides - thegnnews.com
TScan Therapeutics (NASDAQ:TCRX) Will Have To Spend Its Cash Wisely - Yahoo Finance
Order flow analysis tools used on TScan Therapeutics Inc.Options Play & Advanced Swing Trade Entry Plans - Newser
Evaluating TScan Therapeutics Inc. with trendline analysisWeekly Trade Summary & Growth-Oriented Investment Plans - Newser
What recovery options are there for TScan Therapeutics Inc.July 2025 Levels & Proven Capital Preservation Tips - Newser
TScan Therapeutics Inc. recovery potential after sell off2025 Big Picture & Entry Point Confirmation Signals - Newser
TScan Therapeutics’s SWOT analysis: biotech stock faces pivotal year - Investing.com
TScan Therapeutics’s SWOT analysis: biotech stock faces pivotal year By Investing.com - Investing.com Nigeria
How TScan Therapeutics Inc. stock performs during market volatilityJuly 2025 WrapUp & Precise Trade Entry Recommendations - beatles.ru
TScan Therapeutics (TCRX) Gets a Buy from TD Cowen - The Globe and Mail
What moving averages say about TScan Therapeutics Inc.Portfolio Risk Summary & High Win Rate Trade Tips - Newser
Volatility clustering patterns for TScan Therapeutics Inc.2025 Key Highlights & High Accuracy Buy Signal Tips - Newser
TScan Therapeutics (NASDAQ:TCRX) Given “Outperform” Rating at Wedbush - Defense World
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
TScan Therapeutics Reports Q2 2025 Financial Results - TipRanks
Identifying reversal signals in TScan Therapeutics Inc.Trade Risk Summary & Fast Moving Stock Watchlists - Newser
TScan Therapeutics 2025 Q2 Earnings Significant Revenue Growth Despite Deepening Net Loss - AInvest
TScan Therapeutics Inc. Stock Support and Resistance Levels You Should KnowShort-Term Growth Watch with Signal Prediction - Newser
TScan Therapeutics shares rise 2.49% intraday after reporting positive second quarter 2025 results and upcoming trial data. - AInvest
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
May 20 '25 |
Buy |
1.20 |
1,200,000 |
1,440,000 |
7,946,141 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 13 '24 |
Buy |
2.90 |
100,000 |
290,140 |
5,357,347 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 12 '24 |
Buy |
3.01 |
31,800 |
95,629 |
5,257,347 |
| Lynx1 Capital Management LP | 10% Owner |
Nov 15 '24 |
Buy |
4.34 |
947 |
4,114 |
5,225,547 |
| Klencke Barbara | Director |
Sep 23 '24 |
Buy |
5.29 |
5,000 |
26,450 |
45,000 |
| Klencke Barbara | Director |
Aug 23 '24 |
Buy |
5.69 |
5,000 |
28,450 |
35,000 |
| Klencke Barbara | Director |
Aug 26 '24 |
Buy |
5.53 |
5,000 |
27,650 |
40,000 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Option Exercise |
3.38 |
157,186 |
531,520 |
169,402 |
| ZDRAVESKI ZORAN | See Remarks |
Aug 23 '24 |
Sale |
5.78 |
164,686 |
952,116 |
4,716 |
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):